Indeed, recent efforts to introduce SCLC-directed therapy following treatment with osimertinib in EGFR-mutant LUAD cases with a high risk of histological transformation have demonstrated that chemotherapy alone does not prevent histological transformation.27 In general, detection of NE transformation has historically relied upon available tumor tissue as gold-standard level evidence. The gene discussed is EGFR; the disease is neoplasm.